Skip to main content
. 2017 Sep 28;8(50):88034–88042. doi: 10.18632/oncotarget.21366

Table 1. Baseline characteristics of participants.

Characteristic DR n=115(%) DNR n=129(%) Control n=142(%) P1 P2
Age 59.72±11.38 59.05±10.88 57.9±10.61 0.235 0.264
Gender (male) 49(42.61) 54(41.86) 57(40.14) 0.689 0.906
Duration of DM (years) 14.05±7.72 13.98±8.67 - - 0.343
Smoking (yes) 43(37.39) 43(33.33) 44(30.99) 0.281 0.508
Drinking (yes) 47(40.87) 49(37.98) 48(33.80) 0.243 0.645
BMI (Kg/m2) 22.3±6.8 23.5±6.5 24.5±6.3 0.034 0.042
SBP (mmHg) 140.6±20.25 135.8±19.77 127.6±19.42 0.035 0.047
DBP (mmHg) 81.72±12.39 81.96±11.96 79.81±11.90 0.057 0.107
FPG ((mmol/L) 10.19±4.39 8.43±3.57 7.85±4.23 0.008 0.098
TG (mmol/L) 1.59±1.12 1.65±1.37 1.61±1.23 0.302 0.221
TC (mmol/L) 4.16±1.79 3.87±1.86 4.24±1.91 0.351 0.168
HDL (mmol/L) 1.14±0.64 0.97±0.61 1.16±0.52 0.213 0.113
LDL (mmol/L) 2.22±1.31 2.06±1.24 2.19±1.27 0.863 0.761
IGF1 (mg/dL) 207.14±11.38 173.43±12.04 139.58±11.97 0.004 0.007

Notes: P1: DR vs. Control; P2: DR vs. DNR; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TG, triglyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; significant level was adjusted by Bonferroni method.